DEF: Stepan Co. Details 2026 Annual Meeting, 2025 Performance

Stepan Company's definitive proxy statement outlines proposals for its 2026 Annual Meeting, including director elections and executive compensation, alongside a review of its 2025 financial performance.

Summary

• The 2026 Annual Meeting of Stockholders will be held on April 28, 2026, to elect three directors, approve named executive officer compensation on an advisory basis, and ratify Deloitte & Touche LLP as the independent auditor.
• Net income for 2025 decreased by 7% to $46.9 million, or $2.05 per diluted share, compared to $50.4 million, or $2.20 per diluted share, in 2024.
• Adjusted net income for 2025 was $41.7 million, or $1.82 per diluted share, down from $50.5 million, or $2.20 per diluted share, in 2024.
• The Surfactant segment's operating income decreased by 21% to $67.4 million in 2025.
• The Polymer segment's operating income increased by 7% to $43.3 million in 2025.
• Specialty Product operating income increased by 23% to $25.6 million in 2025.
• The company paid $35.0 million in dividends for the full year 2025, marking its 58th consecutive year of increased dividends.
• Executive compensation for 2025 included base salaries, short-term incentives based on Corporate Net Income, Corporate EBITDA, Corporate Free Cash Flow, and Corporate Safety, and long-term incentives comprising SARs, RSUs, and performance shares.
• Corporate Net Income for incentive purposes was $46.9 million, falling below the $50.0 million threshold, resulting in a 0% payout for this metric in the short-term incentive program.
• The CEO pay ratio for 2025 was approximately 1 to 28, with the median employee's annual total compensation at $154,576 and the CEO's at $4,327,042.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing with notable financial declines in key areas like net income and the Surfactant segment, despite some positive governance updates and continued dividend growth. The underperformance against incentive targets suggests operational challenges.

Positives

• The company increased its cash dividend for the 58th consecutive year, demonstrating a strong commitment to shareholder returns.
• The Polymer segment delivered a 7% increase in operating income in 2025.
• The Specialty Product segment achieved a 23% increase in operating income in 2025.
• The 2025 advisory Say-on-Pay vote received 96% stockholder support, indicating strong approval of executive compensation practices.
• An amended and restated equity incentive plan framework was implemented effective April 29, 2025, enhancing long-term alignment and program flexibility.
• The Stepan Company Key Executive Severance Benefit Plan was adopted in 2025 to attract and retain highly qualified executives and promote leadership stability.
• All executive officers were in compliance with the company's stock ownership requirements as of February 2026.
• The company achieved record safety performance, though it fell slightly below its rigorous safety goal.

Negatives

• Net income decreased by 7% to $46.9 million in 2025 from $50.4 million in 2024.
• Adjusted net income decreased to $41.7 million in 2025 from $50.5 million in 2024.
• The Surfactant segment's operating income decreased significantly by 21% in 2025.
• Corporate Net Income, a key metric for short-term incentive awards, was $46.9 million, which was below the $50.0 million Threshold objective, resulting in a 0% payout for this component.
• A Section 16(a) report for Mr. Delgado reporting an equity grant was inadvertently filed late due to administrative error.

Risks

• The Audit Committee oversees enterprise risks, financial risks, and information security risks.
• The Compliance Committee oversees risks related to environmental protection, employee health, safety and security, data privacy, employment, anti-bribery and anti-corruption, product quality compliance, and ethics and compliance training.
• The Human Capital and Compensation Committee reviews risks related to compensation policies and practices, and did not identify any risks reasonably likely to have a material adverse effect on the company during 2025.

Future Outlook

The company anticipates all directors and nominees will attend the 2026 Annual Meeting. There is a possibility of furnishing proxy materials electronically in the future. The Human Capital and Compensation Committee will continue to consider stockholder feedback on Say-on-Pay votes for future executive compensation decisions and will monitor the compensation peer group. The next advisory vote on the frequency of Say-on-Pay votes is expected at the 2029 Annual Meeting.

Management Comments

• "The 2025 NEO compensation was competitive, reasonable, and aligned with both Company performance and stockholder interests."
• "The basic premise of the Company's executive compensation philosophy is to pay for performance."
• "The Company's intention is to foster a performance-driven culture with competitive total compensation as a key driver for all employees."
• "Compensation levels commensurate with Company performance are designed to align the interests of our employees with the interests of our stockholders."
• "The Committee acknowledges and values the feedback from the Company's stockholders on the annual Say-on-Pay vote and believes that these results demonstrate stockholder support of the Company's executive compensation programs."
• "The Board believes that Mr. Stepan's experience puts him in the best position to provide broad leadership for the Board in the role of Chairman as the Board works to deliver value to stockholders."
• "The Board believes that the Company's executive compensation program is appropriately designed and is operating effectively to compensate the Company's NEOs based on achievement of annual and long-term performance goals that are aligned with enhanced stockholder value."

Industry Context

StockSavvy.ai notes that the chemical industry often faces cyclical demand and raw material price volatility. Stepan Company's mixed segment performance, with a significant decline in Surfactant operating income contrasted by growth in Polymer and Specialty Products, reflects these dynamics. The company's consistent dividend increase for 58 consecutive years is a strong signal of stability and commitment to shareholder returns, a characteristic highly valued in mature industrial sectors and a rare achievement that surpasses many industry peers.

Comparison to Industry Standards

• The company utilizes a custom peer group of chemical companies, including AdvanSix Inc., H.B. Fuller Company, Ashland Inc., and The Chemours Company, to benchmark executive compensation, generally targeting median compensation levels.
• The CEO pay ratio of 1 to 28 for 2025 is within the typical range observed for publicly traded companies in the industrial sector.
• The company's record of increasing its dividend for 58 consecutive years is an exceptional achievement, placing it among a select group of companies globally known for long-term shareholder returns, significantly outperforming most industry peers.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are impacted by the 7% decrease in net income and diluted EPS for 2025, but benefit from the 58th consecutive annual dividend increase. Their advisory vote on executive compensation and auditor ratification directly involves them in governance.
• Employees are affected by the company's compensation policies, retirement benefits (SIRP, ESOP II), and profit-sharing contributions. The newly adopted severance plan provides benefits for selected employees in qualifying terminations.
• Customers are indirectly impacted by the performance of the company's segments, which could influence product availability, innovation, and pricing in the long term.
• Creditors are indirectly impacted by the company's financial health and risk management practices, which are overseen by the Audit and Compliance Committees.

Next Steps

• Stockholders will vote on the election of three directors at the Annual Meeting on April 28, 2026.
• Stockholders will cast an advisory vote on named executive officer compensation at the Annual Meeting on April 28, 2026.
• Stockholders will vote on the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 at the Annual Meeting on April 28, 2026.
• The Board of Directors will consider the results of the Say-on-Pay vote for future executive compensation decisions.
• The Audit Committee will consider the results of the auditor ratification vote in future deliberations.
• Stockholders can submit proposals for the 2027 Annual Meeting by November 25, 2026 (Rule 14a-8) or between December 29, 2026, and January 28, 2027 (By-laws).
• Stockholders intending to solicit proxies for director nominees must provide notice by March 1, 2027.

Key Dates

Recommendation

The filing is a routine proxy statement detailing corporate governance, executive compensation, and financial performance for the prior fiscal year (2025). While 2025 saw a decline in net income and a significant drop in the Surfactant segment's operating income, these results would have already been disclosed in the company's Annual Report on Form 10-K. The company's consistent dividend increases for 58 consecutive years demonstrate long-term stability and commitment to shareholder returns, which is a strong positive. However, the underperformance against key incentive metrics for 2025 suggests operational challenges. Given that the financial information is historical and the governance updates are standard, the filing does not present new information that would warrant a change in investment stance. A "hold" recommendation is appropriate as investors would likely have already factored in the 2025 financial performance.

Keywords

Stepan Company, chemicals, surfactants, polymers, specialty products, executive compensation, corporate governance, proxy statement, annual meeting, board of directors, financial performance, dividends, stock ownership, risk management, CEO pay ratio